Jeong-Soo Bae

Dr. Jeong-Soo Bae

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Journal of Atherosclerosis and Thrombosis
Verified
Journal Article
Open access
PDF file
DLDong-Ha Lee
Dong-Ha Lee
HKHyun-Hong Kim
Hyun-Hong Kim
HCHyun-Jeong Cho
Hyun-Jeong Cho
JBJeong-Soo Bae
Jeong-Soo Bae
YYYoung-Bin Yu
Young-Bin Yu
HPHwa-Jin Park
Hwa-Jin Park
Aim: In this study, we investigated the effects of caffeic acid (CAFA), a phenolic acid, on Ca2+-antagonistic cyclic nucleotides associated with the phosphorylation of inositol 1,4,5-trisphosphate receptor (IP3R) and vasodilator-stimulated phosphoprotein (VASP) and the thromboxane A2 (TXA2)-associated microsomal cyclooxygenase-1 (COX-1) activity in collagen (10 μg/mL)-stimulated platelet aggregation. Methods: Washed platelets (108/mL) obtained from Sprague-Dawley rats (6-7 weeks old, male) were preincubated for 3 minutes at 37℃ in the presence of 2 mM exogenous CaCl2 with or without CAFA or other materials, stimulated with collagen (10 μg/mL) for 5 minutes, then used to determine the levels of intracellular cytosolic Ca2+ ([Ca2+]i), TXA2, cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), COX-1 activity, VASP and IP3R phosphorylation. Results: CAFA dose-dependently inhibited collagen-induced platelet aggregation and suppressed the production of TXA2, an aggregation-inducing autacoid associated with the strong inhibition of COX-1 in platelet microsomes exhibiting cytochrome C reductase activity. CAFA dose-dependently inhibited collagen-elevated [Ca2+]i mobilization, which was increased by a cAMP-dependent protein kinase (A-kinase) inhibitor, Rp-8-Br-cAMPS, but not a cGMP-dependent protein kinase (G-kinase) inhibitor, Rp-8-Br-cGMPS. In addition, CAFA significantly increased the formation of cAMP and cGMP, intracellular Ca2+-antagonists that function as aggregation-inhibiting molecules. CAFA increased IP3R (320 kDa) phosphorylation, indicating the inhibition of IP3-mediated Ca2+ release from internal stores (i.e. the dense tubular system) via the IP3R on collagen-activated platelets. Furthermore, CAFA-induced IP3R phosphorylation was strongly inhibited by an A-kinase inhibitor, Rp-8-Br-cAMPS, but only mildly inhibited by a G-kinase inhibitor, Rp-8-Br-cGMPS. These results suggest that the inhibition of [Ca2+]i mobilization by CAFA is resulted from the cAMP/A-kinase-dependent phosphorylation of IP3R. CAFA elevated the phosphorylation of VASP-Ser157, an A-kinase substrate, but not the phosphorylation of VASP-Ser239, a G-kinase substrate. We demonstrate that CAFA increases cAMP and subsequently phosphorylates both IP3R and VASP-Ser157 through A-kinase activation to inhibit [Ca2+]i mobilization and TXA2 production via the inhibition of the COX-1 activity. Conclusions: These results strongly indicate that CAFA is a potent beneficial compound that elevates the level of cAMP-dependent protein phosphorylation in collagen-platelet interactions, which may result in the prevention of platelet aggregation-mediated thrombotic diseases.
1

22 October 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
MPMin-Kyu Park
Min-Kyu Park
HJHyeonha Jang
Hyeonha Jang
JBJeong-Soo Bae
Jeong-Soo Bae
JSJae-Ho Shin
Jae-Ho Shin
HPHwa-Jin Park
Hwa-Jin Park
Background/Objectives: Cardiovascular diseases (CVD) remain the leading cause of diet-related mortality, with hepatic overproduction of very-low-density lipoprotein (VLDL) being a central driver of dyslipidemia. The microsomal triglyceride transfer protein (MTP) is essential for this process, and its activity is negatively regulated by cyclic adenosine monophosphate (cAMP). Theophylline, a methylxanthine found in tea, increases intracellular cAMP. This study aimed to evaluate whether physiologically relevant concentrations of theophylline could beneficially modulate lipoprotein secretion in an ex vivo model of diet-induced MTP activation. Methods: Primary hepatocytes were isolated from rats fed a high-fat, high-carbohydrate diet (HFCD). Cells were treated with 100 µM theophylline, and the secretion of triglyceride (TG), total cholesterol (TC), VLDL-cholesterol (VLDL-C), and HDL-cholesterol (HDL-C) was quantified. Hepatocellular MTP activity and atherogenic indices were also assessed. Results: Compared to untreated control cells, theophylline treatment significantly reduced the secretion of TG by 6% and TC by 24%. Specifically, VLDL-C secretion decreased by 6%, while HDL-C secretion increased substantially by 93%. These lipid-modulating effects were correlated with a 6.9% reduction in MTP activity. Consequently, significant improvements were observed in the atherogenic indices TG/HDL-C, TC/HDL-C, and the atherogenic index (AI) (p < 0.01). Conclusions: Our findings demonstrate that physiologically attainable concentrations of theophylline rebalance lipoprotein secretion by suppressing hepatic MTP activity, shifting the lipid profile toward an anti-atherogenic state. These results highlight the potential of theophylline as a functional dietary component for mitigating diet-induced dyslipidemia and reducing cardiovascular risk.

Verified
Journal Article
Open access
PDF file
MPMin-Kyu Park
Min-Kyu Park
HJHyeonha Jang
Hyeonha Jang
SCSung-Hun Choi
Sung-Hun Choi
JBJeong-Soo Bae
Jeong-Soo Bae
JSJae-Ho Shin
Jae-Ho Shin
HPHwa-Jin Park
Hwa-Jin Park
Polyphenol-rich Oenanthe javanica (Blume) DC. is widely consumed in Asia but its impact on platelet activation, a cause of cardiovascular disease (CVD), is unclear. Collagen-driven platelet activation requires intracellular Ca2+ mobilization and thromboxane A2 (TXA2) production—rational targets for CVD prevention. A hot water extract of O. javanica (OJWE) was profiled by HPLC and tested on collagen-stimulated washed human platelets. Aggregation, Fura-2 [Ca2+]i, and TXB2 were measured, including combinations with verapamil, aspirin, caffeic acid (CA), and chlorogenic acid (CGA). Coagulation (PT/APTT) and ex vivo effects in Sprague–Dawley rats given OJWE (1 or 5 mg day−1, 30 days) were also evaluated. OJWE dose-dependently inhibited collagen-induced aggregation in a Ca2+-dependent manner, synergizing with verapamil, and suppressed [Ca2+]i mobilization and TXA2 production. CA and CGA synergistically enhanced aspirin-mediated COX-1 inhibition. PT/APTT were unaffected in vitro and ex vivo. Dietary OJWE modestly but significantly reduced rat platelet aggregation without altering coagulation. OJWE attenuates platelet activation by selectively targeting Ca2+ mobilization and TXA2 biosynthesis without compromising hemostasis, supporting O. javanica as a functional food with cardiovascular potential at dietary intake.

Verified
Journal Article
Open access
PDF file
MPMin-Kyu Park
Min-Kyu Park
JBJeong-Soo Bae
Jeong-Soo Bae
HJHyeonha Jang
Hyeonha Jang
JSJae-Ho Shin
Jae-Ho Shin
HPHwa-Jin Park
Hwa-Jin Park
WIB-801CE, a standardized Cordyceps militaris extract containing 7.0% cordycepin, suppresses platelet activation induced by thrombin, collagen, and adenosine diphosphate (ADP). As these agonists generate thromboxane A2 (TXA2), which amplifies platelet activation via a self-propagating feedback loop, blockade of TXA2-mediated signaling offers strong antithrombotic potential. TXA2-antagonistic effects were evaluated using U46619, a stable TXA2 analog. Platelet activation was assessed by fibrinogen binding to integrin αIIbβ3, aggregation, and phosphorylation of platelet-activating proteins—PI3K (Tyr458), Akt (Ser473), p38 MAPK (Thr180/Tyr182), ERK1 (Thr202/Tyr204), JNK1 (Thr183/Tyr185)—and inhibitory proteins—VASP (Ser157) and IP3RI (Ser1756)—via immunoblotting. Thrombin-induced fibrin clot retraction, cytotoxicity, coagulation parameters, and antioxidant capacity were also examined. WIB-801CE significantly inhibited U46619-induced fibrinogen binding to integrin αIIbβ3 and platelet aggregation, without inducing cytotoxicity or impairing hemostatic function. It also significantly downregulated the phosphorylation of platelet-activating proteins and upregulated the phosphorylation of platelet-inhibiting proteins. Additionally, WIB-801CE abolished thrombin-induced fibrin clot retraction and demonstrated antioxidant capacity. WIB-801CE disrupts TXA2-driven platelet activation and thrombus stabilization by selectively modulating phosphorylation of key signaling proteins at defined regulatory sites. These properties highlight its promise as a therapeutic candidate for thrombotic disorders with platelet hyperreactivity.